Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]

Corrigendum to “Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy” [Volume 10, Issue 1, January 2025, Pages 217-226]

Saved in:

Bibliographic Details
Main Authors:	Hiddo J.L. Heerspink, Meg Jardine, Donald E. Kohan, Richard A. Lafayette, Adeera Levin, Adrian Liew, Hong Zhang, Irene Noronha, Hernan Trimarchi, Fan Fan Hou, Ronny Renfurm, Todd Gray, Marianne Camargo, Jonathan Barratt
Format:	Article
Language:	English
Published:	Elsevier 2025-04-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024925000695
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN
by: Hiddo J.L. Heerspink, et al.
Published: (2024-04-01)

WCN24-1868 ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I
by: Irene L. Noronha, et al.
Published: (2024-04-01)

Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts
by: Sean J. Barbour, et al.
Published: (2025-04-01)

WCN25-778 AFFINITY study: 1-year results of atrasentan in IgA nephropathy (IgAN)
by: Jonathan Barratt, et al.
Published: (2025-02-01)

WCN25-1638 ALIGN SUBGROUP ANALYSES: CLINICALLY MEANINGFUL UPCR REDUCTIONS SEEN ACROSS SUBGROUPS
by: Meg Jardine, et al.
Published: (2025-02-01)

Erratum to “Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts” [Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1283-1287]
by: Sean J. Barbour, et al.
Published: (2025-07-01)

WCN25-2239 QUANTITATIVE IMAGE ANALYSIS UNCOVERS THE EFFICACY OF THE SELECTIVE ENDOTHELIN A RECEPTOR ANTAGONIST ATRASENTAN IN A RAT MODEL OF IGA NEPHROPATHY
by: Francois Briand, et al.
Published: (2025-02-01)

WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
by: Bruce Hendry, et al.
Published: (2025-02-01)

Vol. 226 (1)
by: Ewelina Rupnik
Published: (2025-07-01)

WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK
by: Sradha Kotwal, et al.
Published: (2025-02-01)

WCN24-1197 EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

LAND ACQUISTION ACT.CAP.226/
Published: (1965)

WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
by: Vlado Perkovic, et al.
Published: (2024-04-01)

WCN24-1132 ACTION3 – Phase 3 study of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS)
by: Jonathon Barratt, et al.
Published: (2024-04-01)

Analysis of the onset characteristics and diagnosis of 217 cases of renal tuberculosis
by: Chongbin Li, et al.
Published: (2025-06-01)

P217: Solving for PS4
by: Elizabeth Cirulli, et al.
Published: (2025-01-01)

WCN25-844 FELZARTAMAB FOR IgA NEPHROPATHY: FINAL RESULTS OF THE IGNAZ STUDY
by: Uptal Patel, et al.
Published: (2025-02-01)

Novel Treatment Paradigms: Primary IgA Nephropathy
by: Haresh Selvaskandan, et al.
Published: (2024-02-01)

WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY
by: Hernán Trimarchi, et al.
Published: (2024-04-01)

Comparison of plasma ALZpath p-Tau217 with Lilly p-Tau217 and p-Tau181 in a neuropathological cohort
by: Divya Bali, et al.
Published: (2025-06-01)

WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
by: Jonathan Barratt, et al.
Published: (2024-04-01)

WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS
by: Dmitrij Kollins, et al.
Published: (2025-02-01)

Research Advances in Separation and Measurement Methodologies of 226Ra in Water
by: Ping XU, et al.
Published: (2025-02-01)

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial
by: Akihiko Koshino, et al.
Published: (2024-02-01)

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
by: K. Melissa Hallow, et al.
Published: (2024-11-01)

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
by: Howard Trachtman, et al.
Published: (2024-04-01)

226. SOChETANNAYa EKSTRAKORPORAL'NAYa TERAPIYa PRI REVMATOIDNOM ARTRITE
by: V A Shevel', et al.
Published: (2000-08-01)

Capsule Endoscopy: A Single Centre Experience with the First 226 Capsules
by: R Enns, et al.
Published: (2004-01-01)

Éloi Laurent, 2011, Social-Écologie, Paris, Flammarion, p. 226.
by: Caroline Lejeune
Published: (2012-05-01)

WCN24-1799 HEMATURIA RESOLUTION WITH THE APRIL-BLOCKING MONOCLONAL ANTIBODY, SIBEPRENLIMAB, IN PATIENTS WITH IgA NEPHROPATHY IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL
by: Jonathan Barratt, et al.
Published: (2024-04-01)

Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR
by: Dana Kim, et al.
Published: (2025-06-01)

Semantic intrusion errors differentiate between amnestic MCI who are plasma p-tau217+ from p-tau217- after adjusting for initial learning strength
by: Rosie E. Curiel Cid, et al.
Published: (2025-07-01)

Reinforcement of Slope Failure on Ponorogo – Pacitan KM 226 Road to Mitigate Landslides
by: Ailia Rizky Akbarrina, et al.
Published: (2025-02-01)

The Immune Regulatory Functions of CD226 and Its Implications in Immune-Mediated Diseases
by: Keyan Liu, et al.
Published: (2025-07-01)

217 closed Salmonella reference genomes using PacBio sequencing
by: Yan Luo, et al.
Published: (2025-02-01)